ENTRY       D11008                      Drug
NAME        Voretigene neparvovec (USAN/INN);
            Voretigene neparvovec-rzyl;
            Luxturna (TN)
PRODUCT     LUXTURNA (Spark Therapeutics)
REMARK      ATC code: S01XA27
            Product: D11008<US>
EFFICACY    Vision loss treatment
  DISEASE   Retinal dystrophy (biallelic RPE65 mutated) [DS:H00527 H00837]
  TYPE      Gene therapy product
COMMENT     Adeno-associated virus serotype 2 (AAV2) vector carrying a functional copy of the RPE65 gene into the retinal pigment epithelial (RPE) cells
TARGET      RPE65 [HSA:6121] [KO:K11158]
  PATHWAY   hsa00830(6121)  Retinol metabolism
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             S SENSORY ORGANS
              S01 OPHTHALMOLOGICALS
               S01X OTHER OPHTHALMOLOGICALS
                S01XA Other ophthalmologicals
                 S01XA27 Voretigene neparvovec
                  D11008  Voretigene neparvovec (USAN/INN) &lt;US&gt;
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Carboxylic-ester hydrolases
                RPE65
                 D11008  Voretigene neparvovec (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             Cellular and gene therapy products
              D11008
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11008
             Cellular and gene therapy products
              D11008
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11008
DBLINKS     CAS: 1646819-03-5
            PubChem: 342581844
///
